Trial Profile
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Bevacizumab
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Male breast cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Acronyms MEDIOLA
- Sponsors AstraZeneca
- 08 Nov 2023 Results published in the Clinical Cancer Research
- 01 Jun 2023 Primary endpoint has not been met (12-week disease control rate (DCR) in patients with previously treated limited or extensive-stage SCLC) , according to Results published in the Lung Cancer.
- 01 Jun 2023 Results (n=40) in patients with relapsed small cell lung cancer cohort published in the Lung Cancer